Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:20 2025-06-13 am EDT			5-day change	1st Jan Change
269.70 ^CHF	-1.06%		+0.56%	+5.56%

Jun. 13	Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	RE
Jun. 11	US FDA approves Nuvation Bio's rare lung cancer drug	RE

ROCHE HOLDINGS AG : Berenberg remains Neutral

Published on 05/16/2025 at 05:59

In a research note, Berenberg analyst Kerry Holford has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged at CHF 290.

Latest news about Roche Holding AG

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	Jun. 13	RE
US FDA approves Nuvation Bio's rare lung cancer drug	Jun. 11	RE
Roche Canada Says Health Canada Authorizes PiaSky	Jun. 11	RE
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	Jun. 11	DJ
EQT leads financing round in SpliceBio	Jun. 11	FW
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	Jun. 10	MT
Roche's Middle Eastern Arm Launches Sustainable Healthcare Lab Certification Initiative	Jun. 10	MT
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients	Jun. 06	RE
ROCHE HOLDINGS AG : Jefferies is Neutral	Jun. 05	ZD
ROCHE HOLDINGS AG : Deutsche Bank remains a Sell rating	Jun. 05	ZD
Formycon receives market approval in Brazil for Lucentis biosimilar	Jun. 05	DP
Swiss Market Index Extends Rally; Roche Gains on EU Win	Jun. 04	MT
Roche's Evrysdi Tablet Gets EU Clearance for Spinal Muscular Atrophy Treatment	Jun. 04	MT
Roche: EU approves Evrysdi tablet for SMA	Jun. 04	CF
EU Approves New Tablet Formulation for Roche's Spinal Muscular Atrophy Treatment	Jun. 04	MT
EU Approves Roche's Evrysdi Tablet For Spinal Muscular Atrophy	Jun. 04	MT
Roche's Evrysdi Tablet Approved By European Commission	Jun. 04	RE
Healthcare Stocks Rise Tuesday -- Healthcare Roundup	Jun. 03	DJ
Swiss Stocks Up as Inflation Turns Negative, OECD Slashes Estimates	Jun. 03	MT
Health insurers in favor of cost containment for drug spending	Jun. 03	DP
Pharmamar Announces Positive Results from the Phase 3Imforte Study of Zepzelca®? (Lurbinectedin) in Combination with Atezolizumab	Jun. 03	CI
Roche: positive results in lung cancer	Jun. 03	CF
Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says	Jun. 03	DJ
Roche Reports Positive Results from Tecentriq-based Combination Treatment for Small Cell Lung Cancer	Jun. 03	MT
Roche: Tecentriq Combined With Lurbinectedin Shows Survival Benefit In Extensive-Stage Small Cell Lung Cancer	Jun. 03	RE

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

Jun. 16 - Kepler Cheuvreux Virtual CEO CFO Conference

More about the company